Phase 4 N=62 Treatment

Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects

Eyelash Hypotrichosis

Bottom Line

View on ClinicalTrials.gov: NCT01229423 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2012

Primary outcome: Primary: Change From Baseline in Eyelash Length at Week 20 — 5.92; 1.10 Millimeter (mm)

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: bimatoprost 0.03% (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: Female
Sponsor: Allergan
Primary completion: Jun 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Change From Baseline in Eyelash Length at Week 20	5.92; 1.10	—
SECONDARY Percentage of Subjects With an Improvement of at Least 1-Point in Global Eyelash Assessment (GEA) Score at Week 20	81.4	—
SECONDARY Change From Baseline in Eyelash Thickness at Week 20	1.39; 0.25	—
SECONDARY Change From Baseline in Eyelash Intensity (Darkness) at Week 20	140.02; -12.97	—
SECONDARY Percentage of Subjects With an Improvement in Satisfaction With Overall Eyelash Prominence at Week 20	83.05	—
SECONDARY Percentage of Subjects Satisfied With Treatment at Week 20	83.1	—

Summary

This study will evaluate the safety and efficacy of LATISSE® (bimatoprost 0.03%) in the augmentation of eyelashes in Korean women.

Eligibility Criteria

Inclusion Criteria

Eyelash prominence assessment of minimal or moderate
Of Korean ethnicity

Exclusion Criteria

Any eye disease or abnormality
Any ocular surgery or use of any eyelash extension or eyelash growth products within 3 months
Any permanent eyeliner within 5 years
Eyelash implants of any kind
Eyelash tint or dye application within 2 months
Use of any treatment that may affect hair growth within 6 months

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01229423). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.